uniQure ( (QURE) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
UniQure’s stock took a notable hit after the FDA withdrew its support for the company’s Biologics License Application (BLA) for the Huntington’s disease gene therapy, AMT-130. The FDA cited insufficient data from Phase I/II studies as the reason for this decision, which came as a surprise given previous communications and designations. This unexpected move has created uncertainty regarding the therapy’s approval timeline, leading to increased volatility and trading volume in uniQure’s stock.
More about uniQure
YTD Price Performance: 275.01%
Average Trading Volume: 3,245,497
Technical Sentiment Signal: Buy
Current Market Cap: $4.17B
For further insights into QURE stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.